BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Turbine, Daiichi Sankyo Expand Virtual Biology Collaboration to Accelerate ADC Discovery

Turbine, a leading virtual biology company, announced the expansion of its collaboration with Daiichi Sankyo following the successful completio...

September 24, 2026 | News

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib for KRAS G12D-Mutated Lung Cancer

Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanc...

September 25, 2026 | News

Sovargen Doses First Patient in Phase Ib/IIa Trial of Kazia’s Paxalisib for Rare Epilepsies

- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology,...

September 24, 2026 | News

Daiichi Sankyo, AstraZeneca’s Enhertu Wins EU Panel Backing for Early Breast Cancer

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% vers...

September 21, 2026 | News

Japan Approves Lundbeck’s Eptinezumab for Migraine Prevention in Adults

Approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) Eptinezumab is the only intravenous (IV) CGRP-targeted preventive treatment ap...

September 18, 2026 | News

Ferronova’s Nanoparticle Platform Shows Promise for More Precise Gastric and Oesophageal Cancer Surgery

Australian medical technology company Ferronova has announced preliminary findings from the MAGMAP multi-centre trial involving 62 gastric and oesopha...

September 17, 2026 | News

Takeda’s Zasocitinib Receives US FDA Priority Review for Plaque Psoriasis

-Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for za...

September 16, 2026 | News

AstraZeneca, Daiichi Sankyo’s ENHERTU Cuts Disease Progression Risk by 37% in HER2-Mutant Lung Cancer

AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial...

September 16, 2026 | News

MEDIPAL, JCR Dose First Patient in Global Phase I/II Trial of JR-446 for Sanfilippo Syndrome

-MEDIPAL HOLDINGS CORPORATION (TSE 7459, MEDIPAL) and JCR Pharmaceuticals Co., Ltd. (TSE 4552, JCR) announced that the first participa...

September 14, 2026 | News

Exegenesis Bio, Modalis Partner to Advance CRISPR-Based DMD Therapy MDL-201

Exegenesis Bio and Modalis Therapeutics Corporation (TOKYO: 4883; "Modalis") announced that they have signed a research collaboration and license agr...

September 14, 2026 | News

GE HealthCare’s Photonova Spectra Photon-Counting CT Secures CE Mark

Following U.S. FDA 510(k) clearance and Japanese regulatory approval, Photonova Spectra has also achieved CE Mark, supporting expanded research and clini...

September 03, 2026 | News

Astellas Reaches US Government Agreement to Lower Medicaid Drug Prices, Strengthen Medicine Supply Chain

Agreement supports commitment to patient access, affordability and innovation – Astellas Pharma Inc. announced that it has reached an agreemen...

September 02, 2026 | News

PENTAX Medical, MAGENTIQ EYE Expand AI-Assisted Colonoscopy Partnership Globally

Expanded agreement combines PENTAX Medical's continued investment in flexible reusable endoscopy with MAGENTIQ's clinically validated AI capabilities, expa...

August 28, 2026 | News

Metabolon Completes Gates Foundation-Funded Metabolomics Studies to Advance Women’s and Infant Health

nnovative sample collection methods developed through Gates Foundation-funded grant enable high-quality metabolomics biomarker discovery in populations fro...

August 27, 2026 | News

Stay Connected